<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424915</url>
  </required_header>
  <id_info>
    <org_study_id>18-058</org_study_id>
    <nct_id>NCT03424915</nct_id>
  </id_info>
  <brief_title>Exercise, Fitness and Tumor Profiling in Breast Cancer Patients</brief_title>
  <official_title>Integrative Profiling of Primary Breast Cancer on the Basis of Divergent Exercise Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to find out how engaging in regular exercise (or not) alters the
      biology of breast tumors as well as the normal tissue (if available) surrounding the tumor.
      The investigators hope that findings from this initial study will guide the design of future
      studies to examine how changes in exercise alter breast tumor biology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>differences in DNA somatic mutational profile</measure>
    <time_frame>2 years</time_frame>
    <description>Eight-μm-thick representative sections of the fresh-frozen sample will be microdissected with a needle under a stereomicroscope (Olympus SZ61), to ensure &gt;70% of tumor cell content as previously described.(36) Matched germline DNA will be microdissected from adjacent normal breast tissue (if available) for each case; to avoid the possibility of morphologically appearing non-neoplastic cells harboring somatic mutations; we will prioritize the microdissection of stromal cells and avoid normal breast ducts and lobules.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Regular exercisers group</arm_group_label>
    <description>There is no treatment on this study, it is a onetime assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exercising group</arm_group_label>
    <description>There is no treatment on this study, it is a onetime assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Harvard Health Professionals survey</intervention_name>
    <description>Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.</description>
    <arm_group_label>Non-exercising group</arm_group_label>
    <arm_group_label>Regular exercisers group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Participant will provide a blood sample</description>
    <arm_group_label>Non-exercising group</arm_group_label>
    <arm_group_label>Regular exercisers group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CPET Procedures</intervention_name>
    <description>CPET with 12-lead ECG</description>
    <arm_group_label>Non-exercising group</arm_group_label>
    <arm_group_label>Regular exercisers group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool sample</intervention_name>
    <description>Research stool sample (within ±1 week of surgery), if possible</description>
    <arm_group_label>Non-exercising group</arm_group_label>
    <arm_group_label>Regular exercisers group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue from the mastectomy or lumpectomy specimen may be obtained, may either acquire a fresh
      frozen research tumor and adjacent normal tissue sample or formalin fixed paraffin embedded
      (FFPE) tissue for molecular profiling Blood and research stool sample (if possible)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MSK clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 21-80 years

          -  Female

          -  Histologically confirmed ER receptor positive (&gt;1% staining), HER2 negative (FISH
             ratio &lt;1.8), untreated operable breast cancer

          -  Stage I to II disease

          -  Scheduled for surgical resection by any type of mastectomy or lumpectomy at MSK

          -  Tumor size ≥1cm by preoperative imaging or physical examination

          -  Categorization into self-reported exercise history exposure classifications as
             follows: (1) exercising: ≥120 minutes of vigorous-intensity exercise/wk for the past
             12 months, and (2) sedentary (non-exercising): ≤ 30 minutes of moderate-intensity
             exercise/week for the past months using the Harvard Health Professionals survey.(34)

          -  Ability to read and understand English

          -  Willing and able to comply with requirements of the protocol

        Exclusion Criteria:

          -  Received any form of neoadjuvant treatment

          -  Presence of any other concurrent, actively treated malignancy

          -  Presence of metastatic disease

          -  If performing a CPET, any of the following contraindications:

               -  Acute myocardial infarction within 3-5 days of any planned study procedures;

               -  Unstable angina

               -  Uncontrolled arrhythmia causing symptoms or hemodynamic compromise

               -  Recurrent syncope

               -  Active endocarditis

               -  Acute myocarditis or pericarditis

               -  Symptomatic severe aortic stenosis

               -  Uncontrolled heart failure

               -  Acute pulmonary embolus or pulmonary infarction within 3 months of any planned
                  study procedures

               -  Thrombosis of lower extremities

               -  Suspected dissecting aneurysm

               -  Uncontrolled asthma

               -  Pulmonary edema

               -  Respiratory failure

               -  Acute non-cardiopulmonary disorders that may affect exercise performance or be
                  aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis).

          -  Mental impairment leading to inability to cooperate

          -  If performing a CPET, room air desaturation at rest ≤ 85%

          -  Any other condition or intercurrent illness that, in the opinion of the investigator,
             makes the participant a poor candidate for the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast Cancer</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Jones, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Jones, PhD</last_name>
    <phone>646-888-8103</phone>
    <email>jonesl3@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neil yengar, MD</last_name>
    <phone>646-888-4714</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent and Follow-up)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent and Follow-up)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent and Follow-up)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent and Follow-up)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Consent and Follow-up)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (Consent and Follow-up)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
    <contact_backup>
      <last_name>Neil Iyengar, MD</last_name>
      <phone>646-888-4714</phone>
    </contact_backup>
    <investigator>
      <last_name>Lee Jones, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Consent and Follow-up)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Jones, PhD</last_name>
      <phone>646-888-8103</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

